Laboratory Investigation

Kidney International (1993) 43, 561–566; doi:10.1038/ki.1993.83

Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism

Jane L Finch, Alex J Brown, Noboru Kubodera, Yashuho Nishii and Eduardo Slatopolsky

Renal Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA, and Chugai Pharmaceutical Company, Limited, Tokyo, Japan

Correspondence: Eduardo Slatopolsky MD, Washington University School of Medicine, Chromalloy American Kidney Center, 4949 Barnes Plaza, Box 8129, St. Louis, Missouri 63110, USA.

Received 19 May 1992; Revised 19 October 1992; Accepted 19 October 1992.

Top

Abstract

Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. 1,25-dihydroxyvitamin D3 has been used with success in the treatment of secondary hyperparathyroidism associated with chronic renal failure. However, frequently 1,25-(OH)2D3 induces hypercalcemia, especially in those patients ingesting large doses of calcium carbonate, precluding the administration of therapeutic doses of 1,25-(OH)2D3. In addition, control of serum phosphorus is a persistent problem in patients maintained on chronic hemodialysis and 1,25-(OH)2D3 treatment can aggravate the hyperphosphatemia. Thus, ideally an analog of 1,25-(OH)2D3 that can suppress PTH with minor effects on calcium (Ca) and phosphate (PO4) metabolism would be an ideal tool to control secondary hyperparathyroidism. We have shown that 22-oxa-1,25-(OH)2D3 (OCT), an analog of 1,25-(OH)2D3 with little calcemie activity, can suppress PTH mRNA in normal rats and in cultured bovine parathyroid cells with equipotency to 1,25-(OH)2D3. To further characterize the differential effects of 1,25-(OH)2D3 and OCT on Ca and PO4 metabolism we performed several experiments in intact and parathyroidectomized (PTX) rats. In metabolic studies in four groups of normal rats 1,25-(OH)2D3 treatment (8 ng/day) significantly increased the intestinal Ca absorption from 15.2 plusminus 2.68% to 30.5 plusminus 2.85% (P < 0.01), while the same dose of OCT had no effect. A dose of 200 ng/day of OCT increased intestinal Ca absorption similarly to the 8 ng/day dose of 1,25-(OH)2D3, from 10.6 plusminus 2.49% to 24.8 plusminus 2.35% (P < 0.01). Results for intestinal PO4 absorption were similar to those for Ca. Eight ng/day of 1,25-(OH)2D3 increased intestinal PO4 absorption from 21.8 plusminus 1.94 to 32.6 plusminus 2.70% (P < 0.01), while the same dose of OCT had no effect. The 200 ng/day dose of OCT increased intestinal PO4 absorption in a manner comparable to the 8 ng/day dose of 1,25-(OH)2D3, from 20.3 plusminus 1.92 to 29.2 plusminus 1.74% (P < 0.01). Similar patterns were observed for urinary Ca and phosphorus excretion. To further characterize the bone-resorbing effects of 1,25-(OH)2D3 and OCT, studies were performed in three groups of PTX rats fed a PO4-deficient diet. 1,25-dihydroxy vitamin D3 (200 ng/day) increased plasma phosphorus to 6.09 plusminus 0.26 mg/dl as compared to 2.41 plusminus 0.33 mg/dl in vehicle-treated animals. On the other hand, plasma phosphorus increased to only 3.55 plusminus 0.23 mg/dl in OCT-treated animals. We conclude that in normal rats OCT is much less active than 1,25-(OH)2D3 in stimulating both intestinal absorption and urinary excretion of Ca and phosphorus. Also as shown in PTX rats fed a PO4-deficient diet, OCT is much less effective in raising plasma phosphorus most likely by bone resorption. Thus, OCT, an analog of 1,25-(OH)2D3, can suppress PTH without significant changes in plasma Ca and phosphorus making it an ideal drug for the treatment of secondary hyperparathyroidism.

Top

References

  1. Chertow BD, Baylink DJ, Wergedal JE, Su MH, Norman AW: Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihy-droxycholecalciferol. J Clin Invest 56:668–678, 1975
  2. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger RNA for pre-pro-parathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270–4273, 1985 | Article | PubMed | ChemPort |
  3. Cantley LK, Russell J, Lettieri D, Sherwood LM: 1,25-dihydroxyvitamin D3 suppresses PTH secretion from bovine parathyroid cells in tissue culture. Endocrinology 117:2114–2119, 1985 | PubMed | ISI | ChemPort |
  4. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo by the rat. J Clin Invest 78:1296–1301, 1986 | PubMed | ISI | ChemPort |
  5. Chan YL, McKay C, Dye E, Slatopolsky E: The effect of 1,25-dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif Tissue Int 38:27–32, 1986 | PubMed | ISI | ChemPort |
  6. Sherrard DJ, Brickman AS, Coburn JW, Singer FR, Maloney N: Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure. Contrib Nephrol 18:92–97, 1980
  7. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin K: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136–2143, 1984 | PubMed | ISI | ChemPort |
  8. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B: Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 34:840–844, 1988 | PubMed | ISI | ChemPort |
  9. Delmez JA, Tindira C, Grooms P, Dusso AS, Windus DW, Slatopolsky E: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium. J Clin Invest 83:1349–1355, 1989 | PubMed | ISI | ChemPort |
  10. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274–279, 1989 | PubMed | ISI | ChemPort |
  11. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis patients. (abstract) Kidney Int 36:1093, 1989 | PubMed | ISI | ChemPort |
  12. Baker LRI, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH: 1,25-(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661–669, 1989 | PubMed | ISI | ChemPort |
  13. Moriniere P, Roussel A, Tahiri Y, de Fremont JF, Maurel G, Jaudon MC, Gueris J, Fournier A: Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: Disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 19:784–787, 1982
  14. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157–161, 1986 | PubMed | ISI | ChemPort |
  15. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch JL, Windus D, Delmez J: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36:897–903, 1989 | PubMed | ISI | ChemPort |
  16. Murayama E, Miyamoto K, Kubodera N, Mori T, Matsunaga I: Synthetic studies of vitamin D3 analogues. VIII. 1) Synthesis of 22-oxavitamin D3 analogues. Chem Pharm Bull (Tokyo) 34:4410–4413, 1987
  17. Abe J, Morikawa M, Miyamoto K, Kaiho S, Fukushima M, Miyaura C, Abe E, Suda T, Nishii Y: Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton. FEB S Lett 226:58–62, 1987
  18. Morimoto S, Imanaka S, Koh E, Shiraishi T, Nabata T, Kitano S, Miyashita Y, Nishii Y, Ogihara T: Comparison of the inhibitions of proliferation of normal and psoriatic fibroblasts by 1,25-dihydroxy vitamin D3 and synthetic analogues of vitamin D3 with an oxygen atom in their side chain. Biochem Int 19:1143–1149, 1989 | PubMed | ISI | ChemPort |
  19. Brown AJ, Ritter CS, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analogue of Vitamin D, 22-Oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728–732, 1989 | PubMed | ISI | ChemPort |
  20. Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int 2:147–151, 1972 | PubMed | ISI | ChemPort |
  21. Slatopolsky E, Bricker NS: The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4:141–145, 1973 | PubMed | ISI | ChemPort |
  22. Maschio GN, Nessitore N, DiAngela A, Bonucci E, Lupo A, Valvo C, Loschiavo E, Faris A, Morachiello P, Previato G, Fiaschi E: Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy. Am J Clin Nutr 33:1546–1554, 1980
  23. Tanaka Y, DeLuca HF: The control of vitamin D by inorganic phosphorus. Arch Biochem Biophys 154:566–570, 1973 | Article | PubMed | ISI | ChemPort |
  24. Slatopolsky E, Gray R, Adams ND, Hruska K, Martin K, Klahr S, DeLuca H: The pathogenesis of secondary hyperparathyroidism in early renal failure, in Fourth International Workshop in Vitamin D, edited by Norman A, Berlin, DeGruyter, 1979, pp. 1209
  25. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB: Hyperparathyroidism and 1,25-dihydroxy-vitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67:876–881, 1988 | PubMed | ISI | ChemPort |
  26. Portale AA, Booth BE, Halloran BP Jr, Morris RC: Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxy-vitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580–1589, 1984 | PubMed | ISI | ChemPort |
  27. Llach F, Massry SG: On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61:601–606, 1985 | PubMed | ISI | ChemPort |
  28. Tessitore N, Venturi A, Adami S, Roncari C, Rugiu C, Corgnati A, Bonucci E, Maschio G: Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure. Miner Electrol Metab 13:38–44, 1987
  29. Lucas PA, Brown RC, Woodhead JS, Coles GA: 1,25-dihy-droxycholecalciferol and parathyroid hormone in advanced chronic renal failure: Effects of simultaneous protein and phosphorus restriction. Clin Nephrol 25:7–10, 1986 | PubMed | ISI | ChemPort |
  30. Slatopolsky E, Rutherford WE, Hruska K, Martin K, Klahr S: How important is phosphate in the pathogenesis of renal osteodystrophy? Arch Intern Med 138:848–852, 1978
  31. Lopez-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 259:F432–F437, 1990 | PubMed | ChemPort |
  32. Finch JL, Brown AJ, Mori T, Nishii Y, Slatopolsky E: Suppression of PTH and decreased action on bone are partially responsible for the low calcemie activity of 22-oxacalcitriol relative to 1,25-(OH)2D3. J Bone Miner Res 7:835–839, 1992 | PubMed | ISI | ChemPort |
  33. Brown AJ, Lopez-Hilker S, Finch JL, Dusso A, Pernalete N, Morrissey J, Mori T, Nishii Y, Slatopolsky E: 22-Oxacalcitriol suppresses parathyroid hormone synthesis and secretion in chronic renal failure. (abstract) J Bone Miner Res 6(S1):209, 1991
  34. Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, Nishii Y, Slatopolsky E, Brown AJ: On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128:1687–1692, 1991 | PubMed | ISI | ChemPort |
  35. Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Nishii Y: Protein-binding properties of 22-oxa-1alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1alpha,25-hydroxyvitamin D3. J Nutr Sci Vitaminol 35:529–533, 1989 | PubMed | ISI | ChemPort |
  36. Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch JL, Mori T, Nishii Y, Brown AJ, Slatopolsky E: On the mechanisms for the selective action of vitamin D analogs. Endocrinology 129:1687–1692, 1991
  37. Zhou LX, Nemere I, Norman AW: 1,25-Dihydroxyvitamin D3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia). J Bone Miner Res 7:457–463, 1992
  38. Civitelli R, Kim YS, Gunsten SL, Fujimori A, Huskey M, Avioli LV, Hruska KA: Nongenomic activation of the calcium message system by vitamin D metabolites in osteoblast-like cells. Endocrinology 127:2253–2262, 1990 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT